RNA-based tumor vaccines in combination with checkpoint inhibitors have also demonstrated durable objective responses in anti-PD1 experienced patients with unresectable melanoma, accompanied by the induction of strong CD4+ and CD8+ T cell immunity against the vaccine antigens (59). Here, CD8A is linked to neoplasm.